171 related articles for article (PubMed ID: 11455023)
21. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Rivory LP; Bowles MR; Robert J; Pond SM
Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
[TBL] [Abstract][Full Text] [Related]
22. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme.
Potter PM; Wolverton JS; Morton CL; Wierdl M; Danks MK
Cancer Res; 1998 Aug; 58(16):3627-32. PubMed ID: 9721871
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
24. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
25. Partial purification and characterization of an esterase acting on the anticancer pro-drugs, 7-ethylcamptothecin derivatives.
Fujita Y; Yaegashi T; Sawada S; Oyama H; Yoshimoto T; Tsuru D
Biol Pharm Bull; 1995 May; 18(5):648-52. PubMed ID: 7492976
[TBL] [Abstract][Full Text] [Related]
26. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
27. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
Morton CL; Wierdl M; Oliver L; Ma MK; Danks MK; Stewart CF; Eiseman JL; Potter PM
Cancer Res; 2000 Aug; 60(15):4206-10. PubMed ID: 10945631
[TBL] [Abstract][Full Text] [Related]
28. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Sai K; Kaniwa N; Ozawa S; Sawada JI
Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
[TBL] [Abstract][Full Text] [Related]
29. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
30. p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11).
Wierdl M; Morton CL; Harris LC; Danks MK; Schuetz JD; Potter PM
J Pharmacol Exp Ther; 2003 Feb; 304(2):699-705. PubMed ID: 12538824
[TBL] [Abstract][Full Text] [Related]
31. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM
Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
[TBL] [Abstract][Full Text] [Related]
35. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Hicks LD; Hyatt JL; Stoddard S; Tsurkan L; Edwards CC; Wadkins RM; Potter PM
J Med Chem; 2009 Jun; 52(12):3742-52. PubMed ID: 19534556
[TBL] [Abstract][Full Text] [Related]
36. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
37. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
Liu P; Ewis HE; Tai PC; Lu CD; Weber IT
J Mol Biol; 2007 Mar; 367(1):212-23. PubMed ID: 17239398
[TBL] [Abstract][Full Text] [Related]
39. Enzyme-prodrug systems: carboxylesterase/CPT-11.
Danks MK; Potter PM
Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
[No Abstract] [Full Text] [Related]
40. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
